Drug Type Monoclonal antibody |
Synonyms TNAX103, TNAX103A |
Target |
Action inhibitors |
Mechanism CD300A inhibitors(CD300a molecule inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Ischemic Stroke | Preclinical | Japan | 08 Sep 2023 | |
Acute Kidney Injury | Preclinical | Japan | 08 Sep 2023 | |
Acute myocardial infarction | Preclinical | Japan | 08 Sep 2023 | |
Spinal Cord Injuries | Preclinical | Japan | 08 Sep 2023 |